WORLDSymposium 2016 attracted over 25 Exhibitors offering a highly interactive forum for discussion of lysosomal diseases with international researchers and health care practitioners More details.
In 2016, over 350 scientific abstracts were presented beginning on Monday, February 29, 2016, and remained open throughout the rest of the conference. More details.
9 Satellite symposia were held from Monday, February 29, 2016 to Thursday, March 3, 2016. Click here for the full schedule.
For the fourth consecutive year, WORLDSymposium began with Emerging Trends in Lysosomal Biology & Lysosomal Diseases: STATE-OF-THE-ART for Experts on Monday, February 29, 2016. More details.
Three postdoctoral Lysosomal Disease Network Fellows were selected by the LDN Steering Committee. More Details.
WORLDSymposium was pleased to announce the 8 recipients of the 2016 Young Investigator Awards. More details.
The WORLDSymposium 2016 New Treatment Award was presented to sebelipase alfa (Kanum™). More details.
WORLDSymposium 2016 Award for Innovation and Accomplishment was presented to Dr. Emil Kakkis. Dr. Kakkis is President and Chief Executive Officer of Ultragenyx Pharmaceutical where he leads a drug development team working on multiple rare and ultra‐rare disease treatments. More details.
WORLDSymposium 2016 Patient Advocate Leader (PAL) Award was received by Barbara Wedehase. Barbara Wedehase has a Masters in Social Work from Washington University in St. Louis, Missouri and is a Board Certified Genetic Counselor.More details.
Christopher P. Austin, MD, Delivered Keynote at WORLDSymposium 2016. Dr. Austin is director of the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH). More details.